Verrica Pharmaceuticals Incis A Biopharmaceutical Company Based In West Chesterpennsylvaniafounded In 2013The Company Focuses On Developing Medical Treatments For Skin Diseasesparticularly Targeting Viral Infections And Conditions Related To Dermatologic Oncologywith A Commitment To Advancing Accessible Therapiesverrica Emphasizes Safety And Efficacy In Its Care Processes One Of Verrica S Key Products Is Ycantha Cantharidin Which Received Fda Clearance In July 2023 As The First Treatment For Molluscum Contagiosum In Patients Aged 2 And Olderthe Company Is Also Working On Vp 315An Oncolytic Peptide For Treating Basal Cell Carcinoma And Squamous Cell Carcinomawith A Phase 2 Trial Already Completed For Basal Cell Carcinomaverrica Collaborates With Partners Like Torii Pharmaceutical Cofor Global Trials And Lytix Biopharma For Oncology Therapiesaiming To Address Unmet Needs In The Field Of Dermatology
